GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Relief Therapeutics Holding SA (XSWX:RLF) » Definitions » Price-to-Owner-Earnings

Relief Therapeutics Holding (XSWX:RLF) Price-to-Owner-Earnings : (As of May. 31, 2024)


View and export this data going back to 2013. Start your Free Trial

What is Relief Therapeutics Holding Price-to-Owner-Earnings?

As of today (2024-05-31), Relief Therapeutics Holding's share price is CHF1.265. Relief Therapeutics Holding does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for Relief Therapeutics Holding's Price-to-Owner-Earnings or its related term are showing as below:

During the past 13 years, the highest Price-to-Owner-Earnings of Relief Therapeutics Holding was 19.20. The lowest was 11.30. And the median was 15.81.


XSWX:RLF's Price-to-Owner-Earnings is not ranked *
in the Biotechnology industry.
Industry Median: 32.61
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2024-05-31), Relief Therapeutics Holding's share price is CHF1.265. Relief Therapeutics Holding's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was CHF-8.35. Therefore, Relief Therapeutics Holding's PE Ratio for today is At Loss.

As of today (2024-05-31), Relief Therapeutics Holding's share price is CHF1.265. Relief Therapeutics Holding's EPS without NRI for the trailing twelve months (TTM) ended in was CHF-1.45. Therefore, Relief Therapeutics Holding's PE Ratio without NRI for today is At Loss.


Relief Therapeutics Holding Price-to-Owner-Earnings Historical Data

The historical data trend for Relief Therapeutics Holding's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Relief Therapeutics Holding Price-to-Owner-Earnings Chart

Relief Therapeutics Holding Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Owner-Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Relief Therapeutics Holding Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Relief Therapeutics Holding's Price-to-Owner-Earnings

For the Biotechnology subindustry, Relief Therapeutics Holding's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Relief Therapeutics Holding's Price-to-Owner-Earnings Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Relief Therapeutics Holding's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Relief Therapeutics Holding's Price-to-Owner-Earnings falls into.



Relief Therapeutics Holding Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Relief Therapeutics Holding's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=1.265/-9.65
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Relief Therapeutics Holding  (XSWX:RLF) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Relief Therapeutics Holding Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Relief Therapeutics Holding's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Relief Therapeutics Holding (XSWX:RLF) Business Description

Traded in Other Exchanges
Address
Avenue de Secheron 15, Fondation EIP, Batiment, Geneva, CHE, CH-1202
Relief Therapeutics Holding SA is engaged in the research, development, and commercialization of biopharmaceutical products. It mainly develops drugs of natural human origin. It has a focus on commercial products and the development program pipeline is focused on three main areas: rare genetic, metabolic disorders, rare connective tissue disorders, and rare lung diseases. Geographically group generates the majority of its revenue from Europe.

Relief Therapeutics Holding (XSWX:RLF) Headlines

No Headlines